Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
PROSOM is an oral small-molecule tablet approved in 1990 for insomnia and multiple sleep-related and neuropsychiatric indications including REM Sleep Behavior Disorder, anxiety, depression, and neurodegenerative diseases. The mechanism of action is not specified in available data, but the broad indication portfolio suggests CNS activity. Patients range from those with primary sleep disorders to those with comorbid psychiatric or neurodegenerative conditions.
As a legacy product approaching loss of exclusivity, PROSOM faces declining market relevance; the brand team is likely contracting or transitioning to generic support and niche indication management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
Worked on PROSOM at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With 169 linked jobs, PROSOM roles span commercial field sales, clinical operations, and regulatory support, reflecting a legacy product in maintenance mode. Career growth is limited by the LOE Approaching lifecycle; positions are more tactical than strategic, focused on sustaining existing market rather than driving innovation or expansion.
169 open roles linked to this drug